Literature DB >> 22094641

Levels of kinesin light chain and dynein intermediate chain are reduced in the frontal cortex in Alzheimer's disease: implications for axoplasmic transport.

Marina Morel1, Céline Héraud, Charles Nicaise, Valérie Suain, Jean-Pierre Brion.   

Abstract

Fast anterograde and retrograde axoplasmic transports in neurons rely on the activity of molecular motors and are critical for maintenance of neuronal and synaptic functions. Disturbances of axoplasmic transport have been identified in Alzheimer's disease and in animal models of this disease, but their mechanisms are not well understood. In this study we have investigated the distribution and the level of expression of kinesin light chains (KLCs) (responsible for binding of cargos during anterograde transport) and of dynein intermediate chain (DIC) (a component of the dynein complex during retrograde transport) in frontal cortex and cerebellar cortex of control subjects and Alzheimer's disease patients. By immunoblotting, we found a significant decrease in the levels of expression of KLC1 and 2 and DIC in the frontal cortex, but not in the cerebellar cortex, of Alzheimer's disease patients. A significant decrease in the levels of synaptophysin and of tubulin-β3 proteins, two neuronal markers, was also observed. KLC1 and DIC immunoreactivities did not co-localize with neurofibrillary tangles. The mean mRNA levels of KLC1, 2 and DIC were not significantly different between controls and AD patients. In SH-SY5Y neural cells, GSK-3β phosphorylated KLC1, a change associated to decreased association of KLC1 with its cargoes. Increased levels of active GSK-3β and of phosphorylated KLC1 were also observed in AD frontal cortex. We suggest that reduction of KLCs and DIC proteins in AD cortex results from both reduced expression and neuronal loss, and that these reductions and GSK-3β-mediated phosphorylation of KLC1 contribute to disturbances of axoplasmic flows and synaptic integrity in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22094641     DOI: 10.1007/s00401-011-0901-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  15 in total

Review 1.  Roles of tau protein in health and disease.

Authors:  Tong Guo; Wendy Noble; Diane P Hanger
Journal:  Acta Neuropathol       Date:  2017-04-06       Impact factor: 17.088

2.  Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.

Authors:  Mathew A Sherman; Michael LaCroix; Fatou Amar; Megan E Larson; Colleen Forster; Adriano Aguzzi; David A Bennett; Martin Ramsden; Sylvain E Lesné
Journal:  J Neurosci       Date:  2016-09-14       Impact factor: 6.167

Review 3.  Connecting the dots between tau dysfunction and neurodegeneration.

Authors:  Bess Frost; Jürgen Götz; Mel B Feany
Journal:  Trends Cell Biol       Date:  2014-08-26       Impact factor: 20.808

Review 4.  Mechanisms associated with the dysregulation of mitochondrial function due to lead exposure and possible implications on the development of Alzheimer's disease.

Authors:  Lakshmi Jaya Madhuri Bandaru; Neelima Ayyalasomayajula; Lokesh Murumulla; Suresh Challa
Journal:  Biometals       Date:  2022-01-20       Impact factor: 2.949

5.  The Alzheimer's β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques.

Authors:  Patty C Kandalepas; Katherine R Sadleir; William A Eimer; Jie Zhao; Daniel A Nicholson; Robert Vassar
Journal:  Acta Neuropathol       Date:  2013-07-03       Impact factor: 17.088

6.  Disruption of axonal transport perturbs bone morphogenetic protein (BMP)--signaling and contributes to synaptic abnormalities in two neurodegenerative diseases.

Authors:  Min Jung Kang; Timothy J Hansen; Monique Mickiewicz; Tadeusz J Kaczynski; Samantha Fye; Shermali Gunawardena
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

7.  Nebula/DSCR1 upregulation delays neurodegeneration and protects against APP-induced axonal transport defects by restoring calcineurin and GSK-3β signaling.

Authors:  Jillian L Shaw; Karen T Chang
Journal:  PLoS Genet       Date:  2013-09-26       Impact factor: 5.917

8.  Epigenetic induction of EGR-1 expression by the amyloid precursor protein during exposure to novelty.

Authors:  Aurélie Hendrickx; Nathalie Pierrot; Bernadette Tasiaux; Olivier Schakman; Jean-Pierre Brion; Pascal Kienlen-Campard; Charles De Smet; Jean-Noël Octave
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

Review 9.  Tau protein modifications and interactions: their role in function and dysfunction.

Authors:  Anna Mietelska-Porowska; Urszula Wasik; Marcelina Goras; Anna Filipek; Grazyna Niewiadomska
Journal:  Int J Mol Sci       Date:  2014-03-18       Impact factor: 5.923

10.  Quantitative analysis of APP axonal transport in neurons: role of JIP1 in enhanced APP anterograde transport.

Authors:  Kyoko Chiba; Masahiko Araseki; Keisuke Nozawa; Keiko Furukori; Yoichi Araki; Takahide Matsushima; Tadashi Nakaya; Saori Hata; Yuhki Saito; Seiichi Uchida; Yasushi Okada; Angus C Nairn; Roger J Davis; Tohru Yamamoto; Masataka Kinjo; Hidenori Taru; Toshiharu Suzuki
Journal:  Mol Biol Cell       Date:  2014-08-27       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.